Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.

"Declarations Competing interests B.S.W. declares no conflicts of interest. S.E.I. has participated on clinical trial executive/steering/publications committees and/or served as an adviser for Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Novo Nordisk, and VTV Therapeutics; has delivered lectures supported by AstraZeneca, Boehringer Ingelheim, and Merck; and has received support for attending meetings from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. I.J.N. has received a grant (directed to his institution) from the National Institutes of Health, consulting fees from Boehringer Ingelheim/Lilly Alliance, and Merck & Co., and has delivered lectures supported by Nestlé Health Sciences. H.K.Y. declares no conflicts of interest. D.K.M. has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lexicon, Merck Sharp & Dohme, and Pfizer Inc. and has received payment for expert testimony from Kirkland & Ellis on behalf of Boehringer Ingelheim. C.P.C. has received research grants from Amgen, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Novo Nordisk, and Pfizer; fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi; and has served on Data and Safety Monitoring Boards for the Veteran’s Administration, Applied Therapeutics, and NovoNordisk. J.P.M., R.F., U.M., and N.B.C. are employees and shareholders of Pfizer Inc. Competing interests B.S.W. declares no conflicts of interest. S.E.I. has participated on clinical trial executive/steering/publications committees and/or served as an adviser for Abbott, AstraZeneca, Boehringer Ingelheim, Esperion, Novo Nordisk, and VTV Therapeutics; has delivered lectures supported by AstraZeneca, Boehringer Ingelheim, and Merck; and has received support for attending meetings from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. I.J.N. has received a grant (directed to his institution) from the National Institutes of Health, consulting fees from Boehringer Ingelheim/Lilly Alliance, and Merck & Co., and has delivered lectures supported by Nestlé Health Sciences. H.K.Y. declares no conflicts of interest. D.K.M. has received consulting fees from AstraZeneca, Boehringer Ingelheim, Lexicon, Merck Sharp & Dohme, and Pfizer Inc. and has received payment for expert testimony from Kirkland & Ellis on behalf of Boehringer Ingelheim. C.P.C. has received research grants from Amgen, Better Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Novo Nordisk, and Pfizer; fees from Aegerion/Amryt, Alnylam, Amarin, Amgen, Applied Therapeutics, Ascendia, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen, Lexicon, Merck, Pfizer, Rhoshan, and Sanofi; and has served on Data and Safety Monitoring Boards for the Veteran’s Administration, Applied Therapeutics, and NovoNordisk. J.P.M., R.F., U.M., and N.B.C. are employees and shareholders of Pfizer Inc."

"Funding This study was sponsored by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA in collaboration with Pfizer Inc., New York, NY, USA. The support provided by Engage Scientific Solutions, funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer, New York, NY, USA, consisted solely of copyediting and formatting for submission; no contribution was made to content."

"Conclusions: In VERTIS CV, ertugliflozin reduced by nearly half the incidence of OSA in patients with T2D and ASCVD. These data contribute to the literature that SGLT2is may have a significant beneficial impact on OSA.: Trial registration.: ClinicalTrials.gov identifier: NCT01986881."